 1

During the earnings call, West Pharmaceuticals discussed their strong first-quarter performance, with 13% organic sales growth and double-digit growth in adjusted earnings per share. The company's gross profit margin improved by 130 basis points, and their adjusted operating profit margin was 17.9%, a 180-basis point increase from the same period last year. West's balance sheet remains strong, with operating cash flow of $57.1 million and a cash balance of $335.3 million. The company expects full-year 2020 net sales guidance to be between $1.95 billion and $1.97 billion, with an estimated organic sales growth of approximately 8%.

# 2

West Pharmaceuticals' mission is to improve patient lives, and the company has been providing innovative, high-quality products and solutions for the containment and delivery of injectable medicines for nearly 100 years. Despite the challenges of the COVID-19 pandemic, the company has remained focused on creating and delivering value to all stakeholders, with two priorities: the well-being and safety of their team members and the continuity of manufacturing and supply of components and solutions to their customers.

# 3

West has been able to maintain operations at normal capacity during the pandemic, leveraging their world-class global manufacturing network to enable the right capabilities, scale, and flexibility to keep up with the increase in demand. The company has seen an increase in customer orders in recent weeks, and they are monitoring order flow to ensure that they are addressing the true demand for their products. West is confident in their long-term growth strategy and is optimistic about emerging from the pandemic experience collectively stronger.